Loading...
•
Mar 31, 2022
Immunic Q1 2022 Earnings Report
Reported financial results for the first quarter ended March 31, 2022 and provided a corporate update.
Key Takeaways
Immunic reported continued momentum in Q1 2022, both financially and within its clinical pipeline programs. They extended their cash runway into the third quarter of 2023 and are advancing their programs to achieve key value inflection points.
Extended cash runway into the third quarter of 2023.
Patient enrollment progressed in both the phase 3 ENSURE program and the phase 2 CALLIPER trial of vidofludimus calcium.
Received Notice of Allowances for composition-of-matter patents for IMU-935.
Top-line data from phase 2 CALDOSE-1 trial of vidofludimus calcium in moderate-to-severe ulcerative colitis is expected next month.
Immunic
Immunic
Forward Guidance
Immunic expects to report initial clinical efficacy data from Part C of their phase 1 clinical trial of IMU-935 in psoriasis patients during the second half and initial clinical safety data from the phase 1 dose escalation trial in metastatic castration-resistant prostate cancer (mCRPC) in the third quarter of this year.